Truist Financial Issues Positive Forecast for Phreesia (NYSE:PHR) Stock Price

Phreesia (NYSE:PHR - Free Report) had its target price lifted by Truist Financial from $31.00 to $34.00 in a research report released on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

PHR has been the subject of several other reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $29.00 target price on shares of Phreesia in a research report on Tuesday. Robert W. Baird reduced their price objective on Phreesia from $34.00 to $30.00 and set an "outperform" rating for the company in a research report on Wednesday. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $34.00 price target on shares of Phreesia in a research report on Thursday, September 5th. DA Davidson reissued a "buy" rating and set a $32.00 price objective on shares of Phreesia in a research report on Thursday, September 5th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $23.00 target price on shares of Phreesia in a research note on Friday, September 27th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, Phreesia has a consensus rating of "Moderate Buy" and a consensus price target of $29.33.

Phreesia Trading Up 2.7 %

Shares of NYSE PHR traded up $0.64 during mid-day trading on Wednesday, hitting $24.78. The stock had a trading volume of 904,922 shares, compared to its average volume of 450,535. The business has a 50 day moving average price of $20.29 and a two-hundred day moving average price of $21.76. Phreesia has a 1 year low of $17.07 and a 1 year high of $29.16. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.77 and a current ratio of 1.77. The firm has a market cap of $1.43 billion, a P/E ratio of -13.91 and a beta of 0.98.

Phreesia (NYSE:PHR - Get Free Report) last issued its quarterly earnings data on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. The firm had revenue of $106.80 million during the quarter, compared to the consensus estimate of $106.33 million. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. The company's quarterly revenue was up 16.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.58) earnings per share. On average, equities analysts anticipate that Phreesia will post -1.23 EPS for the current fiscal year.

Insider Activity at Phreesia

In other news, SVP Amy Beth Vanduyn sold 25,447 shares of the firm's stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $20.93, for a total value of $532,605.71. Following the transaction, the senior vice president now owns 93,470 shares of the company's stock, valued at $1,956,327.10. This trade represents a 21.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Chaim Indig sold 3,089 shares of the company's stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $21.03, for a total transaction of $64,961.67. Following the completion of the transaction, the chief executive officer now owns 1,220,647 shares of the company's stock, valued at approximately $25,670,206.41. The trade was a 0.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 53,569 shares of company stock worth $1,123,014. 5.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Phreesia

A number of hedge funds and other institutional investors have recently modified their holdings of PHR. Deerfield Management Company L.P. Series C purchased a new stake in Phreesia during the second quarter valued at $4,078,000. Champlain Investment Partners LLC lifted its stake in shares of Phreesia by 4.1% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company's stock worth $57,062,000 after acquiring an additional 97,847 shares during the last quarter. Sei Investments Co. boosted its stake in shares of Phreesia by 135.3% during the second quarter. Sei Investments Co. now owns 165,327 shares of the company's stock valued at $3,505,000 after purchasing an additional 95,058 shares during the period. Squarepoint Ops LLC boosted its position in Phreesia by 56.3% in the 2nd quarter. Squarepoint Ops LLC now owns 250,396 shares of the company's stock valued at $5,308,000 after buying an additional 90,215 shares during the period. Finally, State Street Corp grew its stake in Phreesia by 7.1% in the third quarter. State Street Corp now owns 1,327,586 shares of the company's stock worth $30,256,000 after purchasing an additional 88,517 shares in the last quarter. Institutional investors own 92.10% of the company's stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.